Immunogenicity and specificity of norovirus Consensus GII.4 virus-like particles in monovalent and bivalent vaccine formulations. - sprookjes - yvandenbroek - TriplyDB

Immunogenicity and specificity of norovirus Consensus GII.4 virus-like particles in monovalent and bivalent vaccine formulations.

Immunogenicity and specificity of norovirus Consensus GII.4 virus-like particles in monovalent and bivalent vaccine formulations.

http://www.wikidata.org/entity/Q35983587

about

Norovirus immunity and the great escape Vaccines for viral and bacterial pathogens causing acute gastroenteritis: Part I: Overview, vaccines for enteric viruses and Vibrio cholerae Antiviral targets of human noroviruses Vaccine against norovirus.B-Cell Responses to Intramuscular Administration of a Bivalent Virus-Like Particle Human Norovirus Vaccine.The state of norovirus vaccines.Intranasal delivery of a bivalent norovirus vaccine formulated in an in situ gelling dry powder.The dynamics of GII.4 Norovirus in Ho Chi Minh City, Vietnam Chimeric GII.4 norovirus virus-like-particle-based vaccines induce broadly blocking immune responses.Immunization with a consensus epitope from human papillomavirus L2 induces antibodies that are broadly neutralizing Intranasal P particle vaccine provided partial cross-variant protection against human GII.4 norovirus diarrhea in gnotobiotic pigs.Norovirus in healthcare settings.Epidemiology of human noroviruses and updates on vaccine development Epidemiology and evolution of rotaviruses and noroviruses from an archival WHO Global Study in Children (1976-79) with implications for vaccine design.Norovirus P particle efficiently elicits innate, humoral and cellular immunity Identification of a Broadly Cross-Reactive Epitope in the Inner Shell of the Norovirus Capsid.Host genetic factors affect susceptibility to norovirus infections in Burkina Faso Experimental human infection with Norwalk virus elicits a surrogate neutralizing antibody response with cross-genogroup activity Genotype considerations for virus-like particle-based bivalent norovirus vaccine composition.Llama nanoantibodies with therapeutic potential against human norovirus diarrhea.Serological Correlates of Protection against a GII.4 Norovirus.Immunogenicity of Newcastle disease virus vectors expressing Norwalk virus capsid protein in the presence or absence of VP2 protein.Multiple antigenic sites are involved in blocking the interaction of GII.4 norovirus capsid with ABH histo-blood group antigens Static and Evolving Norovirus Genotypes: Implications for Epidemiology and Immunity.Norovirus vaccines and potential antinorovirus drugs: recent advances and future perspectives Preclinical dose-ranging studies of a novel dry powder norovirus vaccine formulation Norovirus vaccines: Correlates of protection, challenges and limitations Identification and characterization of antibody-binding epitopes on the norovirus GII.3 capsid.Norovirus virus-like particle vaccines for the prevention of acute gastroenteritis.Different types of aqueous two-phase systems for biomolecule and bioparticle extraction and purification.Noroviruses: epidemiology, immunity and prospects for prevention.Norovirus Infections in Long-Term Care Facilities.Methods for ascertaining norovirus disease burdens.Characterization of Antigenic Relatedness between GII.4 and GII.17 Noroviruses by Use of Serum Samples from Norovirus-Infected Patients.Prospects and Challenges in the Development of a Norovirus Vaccine.Rapid Responses to 2 Virus-Like Particle Norovirus Vaccine Candidate Formulations in Healthy Adults: A Randomized Controlled Trial.Development a scalable production process for truncated human papillomavirus type-6 L1 protein using WAVE Bioreactor and hollow fiber membrane.Norovirus vaccine against experimental human GII.4 virus illness: a challenge study in healthy adults.Chimeric influenza-virus-like particles containing the porcine reproductive and respiratory syndrome virus GP5 protein and the influenza virus HA and M1 proteins.Detection and molecular characterisation of noroviruses in hospitalised children in Malawi, 1997-2007.

P2860

Q21090486-0F077E79-EB48-43DD-B234-293710A4DD44 Q27004488-E83DCEE0-5D29-4E5B-8339-6D362E99A462 Q30249527-EA981B56-EECE-463C-AC84-99243D565D42 Q33578075-7D9AA95F-7A6E-4B7A-BF09-6B64EC6087BB Q33654573-DFBC3B99-0215-4553-AC9D-BB12785CAC2A Q33678125-383F2EB7-7F68-4A1A-B28B-24DF2B6D7043 Q33703664-E8374745-15F6-4D54-9FEF-F256AB443069 Q33719999-AE0331A9-4937-41E0-9A1B-E9FCC2CAA975 Q33743992-25EB6DD3-28FB-4CFA-8399-A3EB6D89BE9D Q33967341-2071DCA0-1A2F-46D0-A9A2-6DA20E4A6238 Q34059409-EA95BC2E-FE6D-4865-A531-DC742BC8624F Q34134280-D658A475-C808-40FC-B8C8-D745CD7242F5 Q34385139-612C14A6-6B73-4A55-8B9A-226BFB1441E8 Q34639704-7E7A6028-6C96-4B23-AA7F-650802EED10F Q34702360-90F49877-A9CC-4554-BA73-0DED7DD2DE5A Q34785721-8DCC85CD-22D0-46E6-83E2-2E74714FAAE4 Q34873961-D2F96F9D-A215-4A24-A1FC-E705D034F9A0 Q35021149-7B1E4F9B-E292-4364-8C0B-5543C43D23C7 Q35656636-526F5D41-408D-4871-A8DB-A1B4F27CBFEA Q35744232-FB780AF7-7CB1-4BC7-BF0B-9C786A0798EC Q35901978-A2D3CD46-7082-4C16-AE41-BD084B70F410 Q36052875-785DBCD8-454D-439B-A570-1E69F97D58E6 Q36155501-41634CBA-5C0B-4635-BA59-54D9AEA4E26A Q36254157-8D22E233-743E-4E6A-969A-CB4C66AC9BAD Q36275589-8D25889C-56BB-42DC-A22B-A0DDFC0BEE87 Q36642590-8C6B0A19-531E-4961-A51F-32E672FF6494 Q37135476-269E24C8-62DE-4DD3-8E9C-D0AC763298E3 Q37547097-0BBD7F92-3D2B-4E55-83CB-6E786C34C872 Q38081967-86893072-0337-488B-9F5D-CBB4D8E0B71D Q38127392-BE65BE40-B7A5-442D-B538-42B68389F26C Q38322750-AA69C9D6-97C0-4492-A551-9C63EB9B13A7 Q38844351-F7D2F475-13C8-441A-AB94-72D1D3BD6087 Q38869777-3B303A72-A327-436D-88EB-F1CC21B43E7F Q40042470-41597350-3B36-4CBE-8AAC-64D0DB1BECAA Q40102851-2A69D908-9DB6-4E61-A25B-CC6EB450ED4D Q40632645-7A951725-9984-4D8D-B17C-868B85D39CE9 Q40962204-50255224-7A7C-4229-93D5-1AAEBA8560DD Q41743964-743EA40A-8A93-401C-8699-F272DBC6209C Q42203587-5018551D-BBE1-4314-BACA-6C9944F590E1 Q42252299-058022D7-1A4D-4629-9290-8EE8498287E3

P2860

Immunogenicity and specificity of norovirus Consensus GII.4 virus-like particles in monovalent and bivalent vaccine formulations.

http://www.wikidata.org/entity/Q35983587

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Immunogenicity and specificity ...... bivalent vaccine formulations.

@ast

Immunogenicity and specificity ...... bivalent vaccine formulations.

@en

type

label

Immunogenicity and specificity ...... bivalent vaccine formulations.

@ast

Immunogenicity and specificity ...... bivalent vaccine formulations.

@en

prefLabel

Immunogenicity and specificity ...... bivalent vaccine formulations.

@ast

Immunogenicity and specificity ...... bivalent vaccine formulations.

@en

P1433

Q35983587-DFF5F98A-4FA8-4B64-B63B-3A3E7318C929

P1476

Q35983587-39B3C794-F1D5-43E6-BC48-B3AA8B4770D0

P2093

Q35983587-03038E43-1563-47DF-BEAC-A7082BFAEBAC

Q35983587-0B481E33-0FDA-4780-A035-8AF965E498C4

Q35983587-199C6E1F-0C99-49B0-BBB2-57FDB4DCE4A2

Q35983587-2D4A8BF8-3DB2-422F-9F4C-7DF026C4180A

Q35983587-351C88AF-92B1-464B-894F-039DC86DF7C3

Q35983587-7FDB9D38-8630-4442-AF0D-DE111D1B914E

Q35983587-9A52FF19-5922-4592-BE67-5BC8185B444D

P2860

Q35983587-00086D38-21BB-4104-9AB0-EBF208B4D23E

Q35983587-00C26519-7669-4781-88EC-52B860D50666

Q35983587-09BB6E12-255C-4B14-B455-AFC8F8DF27CC

Q35983587-0E814167-C605-46B7-A36A-D047C7DA9928

Q35983587-11FD2467-7D5F-401D-944F-6C2DF06E4E38

Q35983587-137AFE56-93E3-4814-B186-B8480ED35866

Q35983587-150FAF12-A661-4399-BED6-8CE2B9C8A241

Q35983587-197546EF-27BB-4F95-A7D8-6000DBE57FB8

Q35983587-2DA7FBA9-6A54-4BAE-BCCD-2135CFEF9C9D

Q35983587-2E417475-25D9-449B-B522-09306D8FFBFC

P304

Q35983587-EE8E5171-1D65-46CF-8C8E-AB2CB27BCAC6

P31

Q35983587-194EF1A7-EAE5-4832-A983-55D6D84F7EB9

P356

Q35983587-33EEEBB0-B09F-477C-849B-0CD3C9159280

P407

Q35983587-968A93FD-356E-457C-B311-635D8BCF20D0

P433

Q35983587-911B299A-65E8-4220-A729-117095163B65

P478

Q35983587-558920BA-5B6B-4103-9DD4-EE2E7F09FE09

P577

Q35983587-AAA10466-8974-45D7-95BD-E9BD22797ADA

P5875

Q35983587-DBCA21F5-8C24-406E-BB63-0EB3C9FEFA98

P698

Q35983587-AF376F49-4523-45B6-80D6-533A90B11FEA

P921

Q35983587-23A1B223-C3BD-41CC-A7B1-EF3A8946AC48

P932

Q35983587-BA521E1C-0FB6-4AAE-9F21-F7D83C396242

P356

J.VACCINE.2012.03.050

P1433

P1476

Immunogenicity and specificity ...... bivalent vaccine formulations.

@en

P2093

Charles Richardson

http://www.w3.org/2001/XMLSchema#string

Gabriel I Parra

http://www.w3.org/2001/XMLSchema#string

Joel R Haynes

http://www.w3.org/2001/XMLSchema#string

Karin Bok

http://www.w3.org/2001/XMLSchema#string

Kim Y Green

http://www.w3.org/2001/XMLSchema#string

Ross Taylor

http://www.w3.org/2001/XMLSchema#string

Stanislav V Sosnovtsev

http://www.w3.org/2001/XMLSchema#string

P2860

Structural Analysis of Histo-Blood Group Antigen Binding Specificity in a Norovirus GII.4 Epidemic Variant: Implications for Epochal Evolution

Mechanisms of GII.4 norovirus persistence in human populations

Rates of evolutionary change in viruses: patterns and determinants

Herd immunity to GII.4 noroviruses is supported by outbreak patient sera

Influenza-pseudotyped Gag virus-like particle vaccines provide broad protection against highly pathogenic avian influenza challenge.

Molecular epidemiology of genogroup II-genotype 4 noroviruses in the United States between 1994 and 2006

Identification of Genogroup I and Genogroup II broadly reactive epitopes on the norovirus capsid

Binding of Norwalk virus-like particles to ABH histo-blood group antigens is blocked by antisera from infected human volunteers or experimentally vaccinated mice.

Diversity considerations in HIV-1 vaccine selection.

Chimpanzees as an animal model for human norovirus infection and vaccine development.

P304

3580-3586

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.VACCINE.2012.03.050

http://www.w3.org/2001/XMLSchema#string

P407

P433

24

http://www.w3.org/2001/XMLSchema#string

P478

30

http://www.w3.org/2001/XMLSchema#string

P577

2012-03-31T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

223982490

http://www.w3.org/2001/XMLSchema#string

P698

22469864

http://www.w3.org/2001/XMLSchema#string

P921

P932

3359014

http://www.w3.org/2001/XMLSchema#string